Pulmonary Passage is a Major Obstacle for Intravenous Stem Cell Delivery: The Pulmonary First-Pass Effect

By U. Fischer, M. Harting, Fernando Jimenez, W. O. Monzon-Posadas, H. Xue, S. Savitz, G. Laine, C. Cox. Stem Cells and Development, 2009

1,212 citations recorded by the source corpus.

Subfields: Biomaterials, Genetics, Surgery

View Paper: https://www.semanticscholar.org/paper/3d3c2bb13fe7bdc0eea4822bda72b7e338cf5f55

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

1. A. Weiss
2. M. Dahlke
3. H. Schlitt
4. E. Geissler
5. F. Popp
6. A. Kroemer
7. V. Benseler
8. E. Eggenhofer

Citations in the corpus

• Mesenchymal stem cells are short-lived and do not migrate beyond the lungs after intravenous infusion (2012, background): “Tracking studies have shown that the majority of MSC localize to the lungs after intravenous infusion (Barbash et al., 2003; Kraitchman et al., 2005; Fischer et al., 2009; Assis et al., 2010).”
• Immunomodulation by Mesenchymal Stem Cells (MSCs): Mechanisms of Action of Living, Apoptotic, and Dead MSCs (2019, background): “Within 24 h after being trapped in the pulmonary system a major decrease in the number of viable MSCs can be observed (29, 30).”